热门资讯> 正文

HUTCHMED在AACR-NCI-EOTTC上展示了HMPL-A251临床前数据，显示强效HER 2靶向PI 3 K/PIKK抑制剂，具有强大的抗肿瘤活性和低毒性

2025-10-23 14:59

First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities
Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate advantages, with directed delivery and low plasma exposure of free payload —
Preclinical data shows robust antitumor activity with synergistic and bystander killing effects

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。